New hope for rare blood cancer: drug combo targets relapsed lymphoma
Disease control
Not yet recruiting
This study tests whether adding the drug sugemalimab to standard chemotherapy can help people with a rare type of blood cancer (extranodal NK/T-cell lymphoma) that has returned or stopped responding to previous treatment. About 150 adults will receive either the combination or a …
Phase: PHASE3 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:52 UTC